Free-flowing solid formulations with improved bio-availability of poorly water soluble drugs and process for making the same

• US 20070009559A1
• Filed: 07/27/2006
• Published: 01/11/2007
• Est. Priority Date: 12/12/2002
• Status: Abandoned Application

• Current Assignee: Amy Nguyen, Bricini Dema-Ala, Edward Alosio, Wenji Li
• Original Assignee: Amy Nguyen, Bricini Dema-Ala, Edward Alosio, Wenji Li
• Inventors: Li, Wenji, Dema-Ala, Bricini, Nguyen, Amy, Alosio, Edward
• Application Number:
  US11/494,129
• Publication Number:
  US 20070009559A1
• Time in Patent Office: Days
• US Class Current: 424/400
• CPC Class Codes: A61K 9/0095 Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches A61K9/0007 takes precedence; eatable gels or foams A61K9/0056; oral mucosa adhesive forms A61K9/006
• CPC Class Codes: A61K 9/06 Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels composition of ointments, creams or gels A61K47/00
• CPC Class Codes: A61K 9/1611 Inorganic compounds
• CPC Class Codes: A61K 9/1617 Organic compounds, e.g. phospholipids, fats
• CPC Class Codes: A61K 9/2077 Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
• CPC Class Codes: A61P 3/06 Antihyperlipidemics

Abstract

A free-flowing solid formulations of drugs or pharmaceutical agents which have poor aqueous solubility are obtained by admixing a liquid or gel composition that includes 1 to 30 percent by weight of the drug, 5 to 60 percent by weight of a surfactant, 10 to 40 percent by weight of water; 1 to 20 percent by weight of unsaturated fatty acid ester, 0 to 50 percent by weight water miscible pharmaceutically acceptable polyol and 1 to 10 percent by weight of phospholipid with a pharmaceutically acceptable suitable solid carrier and thereafter drying the admixture. The free-flowing powder is suitable for being formed into tablets or capsules. The drug or pharmaceutical agent is solubilized in the formulation and has significantly improved bio-availability when compared to the drug tested in its pure form.

Claims

1. A composition comprising:

1 to 30 percent by weight of a pharmaceutical agent or drug that has poor solubility in water;

5 to 60 percent by weight of a pharmaceutically acceptable surfactant;

10 to 40 percent by weight of water;

1 to 20 percent by weight of a pharmaceutically acceptable unsaturated fatty acid ester;

0 to 50 percent by weight of a pharmaceutically acceptable water miscible polyol, and

1 to 10 percent by weight of a pharmaceutically acceptable phospholipid.

2. A composition in accordance with claim 1 that is a gel.

3. A composition in accordance with claim 1 that is a liquid.

4. A composition in accordance with claim 1 where the drug has less than 0.0001 percent weight by weight solubility in water.

5. A composition in accordance with claim 1 comprising:

pharmaceutical agent or drug 2 to 15 percent by weight;

surfactant 20 to 40 percent by weight;

water 15 to 30 percent by weight;

unsaturated fatty acid ester 4 to 10 percent by weight;

water miscible polyol 1 to 30 percent by weight;

phospholipid 1 to 5 percent by weight.

6. A composition in accordance with claim 4 comprising:

pharmaceutical agent or drug 2 to 15 percent by weight;

surfactant 20 to 40 percent by weight;

water 15 to 30 percent by weight;

unsaturated fatty acid ester 4 to 10 percent by weight;

water miscible polyol 1 to 30 percent by weight;

phospholipid 1 to 5 percent by weight.

7. A composition in accordance with claim 1 where the drug is selected from the group consisting of hormones, cholesterol lowering drugs, anti-acids and anti-allergy drugs.

8. A composition in accordance with claim 1 where the drug is selected from the group consisting of progesterone, lovastatin, simvastatin, famotidine, loratadine, oxametacine, piroxicam, hydrochlorothiazide, acrivastine, estradiol and its esters having estradiol-like activity, norethindrone, estrone and its esters having estrone-like activity, nifedipine, oxymetholone, testosterone and derivatives having testosterone-like activity, carvedilol, chlorthalidone, guanfacine hydrochloride, trandolapril, enalapril maleate, felodipine, amlodipine, colestipol hydrochloride, clofibrate, gemfibrozil, fenofibrate, atorvastatin and pravastatin.

9. A composition in accordance with claim 1 where the surfactant is selected from the group consisting of polyoxyethylene sorbitan fatty acid esters, polyoxyethylene alkyl ethers, polyoxyethylene castor oil derivatives, polyoxyethylene stearates, and saturated polyglycolized glycerides.

10. A composition in accordance with claim 1 where the unsaturated fatty acid is selected from the group consisting of ethyl linoleate, palmitoleic acid, oleic acid and linoleic acid.

11. A composition in accordance with claim 1 where the water miscible polyol is selected from the group consisting of propylene glycol, glycerol, diethylene glycol, diethylene glycol monoethyl ether and polyethylene glycol.

12. A composition in accordance with claim 1 where the phospholipid is selected from the group consisting of lecithin, phosphatidylethanolamine, phosphatidylserine and phosphatidylinositol.

13. A composition comprising:

1 to 30 percent by weight of a pharmaceutical agent or drug that has poor solubility in water;

5 to 60 percent by weight of a pharmaceutically acceptable surfactant selected from the groups consisting of polyoxyethylene sorbitan fatty acid esters, polyoxyethylene alkyl ethers, polyoxyethylene castor oil derivatives, polyoxyethylene stearates, and saturated polyglycolized glycerides;

10 to 40 percent by weight of water;

1 to 20 percent by weight of a pharmaceutically acceptable unsaturated fatty acid ester selected from the groups consisting of ethyl linoleate, palmitoleic acid, oleic acid and linoleic acid;

0 to 50 percent by weight of a pharmaceutically acceptable water miscible polyol selected from the group consisting of propylene glycol, glycerol, diethylene glycol, diethylene glycol monoethyl ether and polyethylene glycol, and

1 to 10 percent by weight of a pharmaceutically acceptable phospholipid selected from the group consisting of lecithin, phosphatidylethanolamine, phosphatidylserine and phosphatidylinositol.

14. A composition in accordance with claim 13 where the drug has less than 0.0001 percent weight by weight solubility in water.

15. A composition in accordance with claim 14 comprising:

pharmaceutical agent or drug 2 to 15 percent by weight;

surfactant 20 to 40 percent by weight;

water 15 to 30 percent by weight;

unsaturated fatty acid ester 4 to 10 percent by weight;

water miscible polyol 1 to 30 percent by weight;

phospholipid 1 to 5 percent by weight.

16. A composition in accordance with claim 13 where the drug is selected from the group consisting of hormones, cholesterol lowering drugs, anti-acids and anti-allergy drugs.

17. A composition in accordance with claim 13 where the drug is selected from the group consisting of progesterone, lovastatin, simvastatin, famotidine, loratadine, oxametacine, piroxicam, hydrochlorothiazide, acrivastine, estradiol and its esters having estradiol-like activity, norethindrone, estrone and its esters having estrone-like activity, nifedipine, oxymetholone, testosterone and derivatives having testosterone-like activity, carvedilol, chlorthalidone, guanfacine hydrochloride, trandolapril, enalapril maleate, felodipine, amlodipine, colestipol hydrochloride, clofibrate, gemfibrozil, fenofibrate, atorvastatin and pravastatin.

18-41. -41. (canceled)